Literature DB >> 6177755

Genetic regulation of the immune response to hepatitis B surface antigen (HBsAg). I. H-2 restriction of the murine humoral immune response to the a and d determinants of HBsAg.

D R Milich, F V Chisari.   

Abstract

In hepatitis B virus (HBV) infection correlation of disease activity with major histocompatibility complex (MHC) antigens has been suggested. However, no data are available regarding the nature and regulation of the immune response to the surface viral protein (HBsAg). This consideration and the current emphasis on production of an HBV vaccine led us to investigate the humoral immune response to HBsAg in inbred strains of mice to assess genetic factors that may regulate the humoral anti-HBs response. Studies with H-2 congenic and noncongenic inbred strains revealed the T-dependent humoral immune responses to the group-specific a and subtype-specific d determinants of HBsAg are regulated by gene(s) mapping to the murine MHC. The H-2q haplotype conferred high responsiveness, the H-2s,f haplotypes conferred low to nonresponsiveness, and the H-2a,b,d,k haplotypes were intermediate. Studies of H-2 recombinant strains allowed tentative mapping of regulation of the anti-a response and possibly the anti-d response to the K/I-A, I-B region of the MHC. The H-2-restricted regulation of the humoral immune response to HBsAg was circumvented by immunization with 10-fold higher HBsAg doses. These findings demonstrate a clear linkage between the murine MHC and the regulation of the immune response to specific determinants on HBsAg.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 6177755

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  30 in total

1.  HLA tissue types in nonresponders to hepatitis B vaccine.

Authors:  B Durupinar; G Okten
Journal:  Indian J Pediatr       Date:  1996 May-Jun       Impact factor: 1.967

2.  Response to HBV vaccination in patients with severe liver disease. Absence of an HLA effect.

Authors:  D H Van Thiel; J S Gavaler
Journal:  Dig Dis Sci       Date:  1992-09       Impact factor: 3.199

3.  Distinct regulation of humoral and cellular immunities to hepatitis B surface antigen.

Authors:  H Y Lei; S C Lee; C K Yu
Journal:  Immunology       Date:  1990-11       Impact factor: 7.397

4.  The cellular basis for lack of antibody response to hepatitis B vaccine in humans.

Authors:  E Egea; A Iglesias; M Salazar; C Morimoto; M S Kruskall; Z Awdeh; S F Schlossman; C A Alper; E J Yunis
Journal:  J Exp Med       Date:  1991-03-01       Impact factor: 14.307

5.  Hepatitis B synthetic immunogen comprised of nucleocapsid T-cell sites and an envelope B-cell epitope.

Authors:  D R Milich; J L Hughes; A McLachlan; G B Thornton; A Moriarty
Journal:  Proc Natl Acad Sci U S A       Date:  1988-03       Impact factor: 11.205

6.  Nature of immunological non-responsiveness to hepatitis B vaccine in healthy individuals.

Authors:  S S Chiou; K Yamauchi; T Nakanishi; H Obata
Journal:  Immunology       Date:  1988-07       Impact factor: 7.397

7.  Igh allotype-linked control of immune complex-type hypersensitivity induced by hepatitis B surface antigen.

Authors:  H Y Lei; S C Lee
Journal:  Immunology       Date:  1989-12       Impact factor: 7.397

8.  Partial delipidation improves the T-cell antigenicity of hepatitis B virus surface antigen.

Authors:  Isabelle Desombere; Annick Willems; Yvonne Gijbels; Geert Leroux-Roels
Journal:  J Virol       Date:  2006-04       Impact factor: 5.103

9.  Failure of preexisting antibody against hepatitis B surface antigen to prevent subsequent hepatitis B infection.

Authors:  P D Swenson; M R Escobar; R L Carithers; T J Sobieski
Journal:  J Clin Microbiol       Date:  1983-08       Impact factor: 5.948

Review 10.  The optimization of helper T lymphocyte (HTL) function in vaccine development.

Authors:  J Alexander; J Fikes; S Hoffman; E Franke; J Sacci; E Appella; F V Chisari; L G Guidotti; R W Chesnut; B Livingston; A Sette
Journal:  Immunol Res       Date:  1998       Impact factor: 2.829

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.